Profile data is unavailable for this security.
About the company
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
- Revenue in USD (TTM)142.05m
- Net income in USD-332.97m
- Incorporated2020
- Employees53.00
- LocationAssertio Holdings Inc100 S. Saunders Road, Suite 300LAKE FOREST 60045United StatesUSA
- Phone+1 (224) 419-7106
- Fax+1 (302) 636-5454
- Websitehttps://www.assertiotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellectar Biosciences Inc | 0.00 | -50.98m | 88.55m | 20.00 | -- | 9.01 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Hongchang International Co Ltd | 2.67m | -365.80k | 103.82m | 8.00 | -- | 2.62 | -- | 38.93 | -0.0006 | -0.0006 | 0.0055 | 0.0763 | 0.0993 | -- | 175.86 | -- | -1.36 | -7.98 | -1.42 | -10.94 | 3.03 | 11.47 | -13.72 | -64.88 | 5.86 | -- | 0.2263 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Elutia Inc | 25.05m | -49.46m | 106.65m | 54.00 | -- | -- | -- | 4.26 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 111.04m | 1.00 | -- | 36.81 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 120.37m | 384.00 | -- | 0.3709 | -- | 0.3024 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| I-Mab ADR | 3.80m | -201.61m | 121.32m | 220.00 | -- | 0.5122 | -- | 31.91 | -2.42 | -2.42 | 0.0457 | 2.93 | 0.0083 | -- | -- | 17,284.22 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Assertio Holdings Inc | 142.05m | -332.97m | 129.37m | 53.00 | -- | 0.9618 | -- | 0.9107 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Mediwound Ltd | 19.85m | -12.75m | 134.70m | 100.00 | -- | 5.94 | -- | 6.79 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 150.60m | 459.00 | -- | -- | -- | 1.46 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| OptiNose Inc | 74.02m | -30.75m | 152.08m | 132.00 | -- | -- | -- | 2.05 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 153.23m | 135.00 | -- | 6.24 | -- | 8.69 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Biostem Technologies Inc | 58.01m | 159.39k | 154.04m | 67.00 | -- | 23.38 | 401.17 | 2.66 | -0.0865 | -0.0865 | 3.60 | 0.4064 | 2.38 | 5.17 | 2.78 | -- | 0.6536 | -- | 9.45 | -- | 94.16 | -- | 0.2748 | -- | 1.10 | 1.23 | 0.3959 | -- | -- | -- | -- | -- | -- | -- |
| ASP Isotopes Inc | 1.27m | -19.62m | 165.64m | 76.00 | -- | 14.79 | -- | 130.08 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to Assertio Holdings Inc's reporting currency: US Dollar USD
35.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Mar 2024 | 9.27m | 9.75% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.85m | 6.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.85m | 5.10% |
| AQR Capital Management LLCas of 31 Mar 2024 | 3.23m | 3.40% |
| Russell Investment Management LLCas of 31 Mar 2024 | 2.35m | 2.47% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 2.09m | 2.20% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.05m | 2.15% |
| TD Securities (USA) LLCas of 31 Mar 2024 | 1.58m | 1.67% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.53m | 1.61% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 1.13m | 1.19% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
